Mazdutide (also known as IBI362) is not solely a GLP-1 agonist. Instead, it is a dual agonist that activates both the GLP-1 (glucagon-like peptide-1) receptor and the glucagon receptor. This dual mechanism combines the benefits of GLP-1 receptor activation (e.g., improved blood sugar control, appetite suppression) with glucagon receptor activation (e.g., increased energy expenditure), potentially enhancing its efficacy for weight loss and metabolic regulation compared to single GLP-1 agonists like semaglutide or liraglutide.
In summary:
●GLP-1 agonists mimic the natural GLP-1 hormone.
●Mazdutide goes further by also targeting glucagon receptors, making it a dual agonist with a broader mechanism of action.
This design aims to optimize outcomes in obesity and type 2 diabetes treatment.
